Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Toxicol Pathol ; 49(5): 1117-1125, 2021 07.
Artigo em Inglês | MEDLINE | ID: mdl-34077280

RESUMO

The most common target organ for toxicity in the endocrine system is the adrenal gland, and its function is dependent upon the hypothalamus and pituitary gland. Histopathologic examination of the adrenal glands and pituitary gland is routinely performed in toxicity studies. However, the function of the adrenal gland is not routinely assessed in toxicity studies. Assessment of adrenal cortical function may be necessary to determine whether a histopathologic finding in the adrenal cortex results in a functional effect in the test species. As juvenile toxicity studies are more commonly performed in support of pediatric indications for pharmaceuticals, it is important to establish historical control data for adrenal gland function. In this study, adrenal cortical function was assessed in control neonatal and weanling beagle dogs as part of an ongoing juvenile toxicology program. Measurements of serum adrenocorticotropic hormone (ACTH), cortisol prior to and following administration of exogenous ACTH, and aldosterone were conducted beginning at 2 weeks of age continuing through 26 weeks of age. Serum electrolyte concentrations were determined at 4, 13, and 26 weeks of age. Dogs as young as 2 weeks of age synthesize and secrete adrenal cortical hormones and exhibit a functional hypothalamic pituitary adrenal axis.


Assuntos
Córtex Suprarrenal , Sistema Hipotálamo-Hipofisário , Sistema Hipófise-Suprarrenal , Glândulas Suprarrenais , Hormônio Adrenocorticotrópico , Animais , Animais Recém-Nascidos , Cães
2.
Toxicol Pathol ; 47(4): 528-541, 2019 06.
Artigo em Inglês | MEDLINE | ID: mdl-31064296

RESUMO

In a juvenile toxicology program, an unexpected finding of vacuolation of inner nuclear, ganglion cell, and nerve fiber layers of the retina was observed microscopically in routine Davidson's fixed and hematoxylin and eosin-stained tissue sections of eyes in beagle dogs at approximately 5 weeks of age. There was no necrosis or degeneration of the affected cells and no associated inflammation. Fluorescein angiography revealed no vascular leakage. Optical coherence tomography (OCT) indicated swollen cells in the same layers of the retina as observed at light microscopic examination. Transmission electron microscopy revealed that the retinal vacuolation likely was consistent with intracellular swelling of amacrine, horizontal, and/or bipolar cells of the inner nuclear layer as affected cells had an expanded cytoplasm but contained normal nucleus and organelles. As assessed by animal behavior and full-field electroretinography, the retinal vacuolation appeared to have no impact on visual function. Retinal vacuolation was seen in approximately 40% of dogs at 5 weeks of age using OCT and/or light microscopic examination. Because the change was transient and age related, did not result in degenerative retinal changes, and was not present in dogs older than 5 weeks of age, it was considered a background developmental observation in beagle dogs.


Assuntos
Retina/crescimento & desenvolvimento , Toxicologia/métodos , Vacúolos/fisiologia , Fatores Etários , Animais , Animais Recém-Nascidos , Cães , Angiofluoresceinografia , Microscopia , Microscopia Eletrônica de Transmissão , Retina/diagnóstico por imagem , Tomografia de Coerência Óptica
3.
Mol Cancer Ther ; 18(1): 3-16, 2019 01.
Artigo em Inglês | MEDLINE | ID: mdl-30352802

RESUMO

PTC299 was identified as an inhibitor of VEGFA mRNA translation in a phenotypic screen and evaluated in the clinic for treatment of solid tumors. To guide precision cancer treatment, we performed extensive biological characterization of the activity of PTC299 and demonstrated that inhibition of VEGF production and cell proliferation by PTC299 is linked to a decrease in uridine nucleotides by targeting dihydroorotate dehydrogenase (DHODH), a rate-limiting enzyme for de novo pyrimidine nucleotide synthesis. Unlike previously reported DHODH inhibitors that were identified using in vitro enzyme assays, PTC299 is a more potent inhibitor of DHODH in isolated mitochondria suggesting that mitochondrial membrane lipid engagement in the DHODH conformation in situ is required for its optimal activity. PTC299 has broad and potent activity against hematologic cancer cells in preclinical models, reflecting a reduced pyrimidine nucleotide salvage pathway in leukemia cells. Archived serum samples from patients treated with PTC299 demonstrated increased levels of dihydroorotate, the substrate of DHODH, indicating target engagement in patients. PTC299 has advantages over previously reported DHODH inhibitors, including greater potency, good oral bioavailability, and lack of off-target kinase inhibition and myelosuppression, and thus may be useful for the targeted treatment of hematologic malignancies.


Assuntos
Neoplasias Hematológicas/tratamento farmacológico , Imidazóis/administração & dosagem , Oxirredutases atuantes sobre Doadores de Grupo CH-CH/antagonistas & inibidores , Tiazóis/administração & dosagem , Fator A de Crescimento do Endotélio Vascular/genética , Animais , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Di-Hidro-Orotato Desidrogenase , Neoplasias Hematológicas/sangue , Neoplasias Hematológicas/enzimologia , Humanos , Imidazóis/farmacologia , Células K562 , Camundongos , Oxirredutases atuantes sobre Doadores de Grupo CH-CH/sangue , Tiazóis/farmacologia , Ensaios Antitumorais Modelo de Xenoenxerto
4.
Hum Mol Genet ; 25(10): 1885-1899, 2016 05 15.
Artigo em Inglês | MEDLINE | ID: mdl-26931466

RESUMO

Spinal muscular atrophy (SMA) is caused by the loss or mutation of both copies of the survival motor neuron 1 (SMN1) gene. The related SMN2 gene is retained, but due to alternative splicing of exon 7, produces insufficient levels of the SMN protein. Here, we systematically characterize the pharmacokinetic and pharmacodynamics properties of the SMN splicing modifier SMN-C1. SMN-C1 is a low-molecular weight compound that promotes the inclusion of exon 7 and increases production of SMN protein in human cells and in two transgenic mouse models of SMA. Furthermore, increases in SMN protein levels in peripheral blood mononuclear cells and skin correlate with those in the central nervous system (CNS), indicating that a change of these levels in blood or skin can be used as a non-invasive surrogate to monitor increases of SMN protein levels in the CNS. Consistent with restored SMN function, SMN-C1 treatment increases the levels of spliceosomal and U7 small-nuclear RNAs and corrects RNA processing defects induced by SMN deficiency in the spinal cord of SMNΔ7 SMA mice. A 100% or greater increase in SMN protein in the CNS of SMNΔ7 SMA mice robustly improves the phenotype. Importantly, a ∼50% increase in SMN leads to long-term survival, but the SMA phenotype is only partially corrected, indicating that certain SMA disease manifestations may respond to treatment at lower doses. Overall, we provide important insights for the translation of pre-clinical data to the clinic and further therapeutic development of this series of molecules for SMA treatment.


Assuntos
Isocumarinas/administração & dosagem , Atrofia Muscular Espinal/tratamento farmacológico , Atrofia Muscular Espinal/genética , Piperazinas/administração & dosagem , Bibliotecas de Moléculas Pequenas/farmacocinética , Proteína 2 de Sobrevivência do Neurônio Motor/genética , Processamento Alternativo/efeitos dos fármacos , Processamento Alternativo/genética , Animais , Sistema Nervoso Central/metabolismo , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Éxons/genética , Humanos , Leucócitos Mononucleares/efeitos dos fármacos , Camundongos , Camundongos Transgênicos , Atrofia Muscular Espinal/sangue , Atrofia Muscular Espinal/patologia , Splicing de RNA/efeitos dos fármacos , Splicing de RNA/genética , Pele/metabolismo , Bibliotecas de Moléculas Pequenas/administração & dosagem , Proteína 2 de Sobrevivência do Neurônio Motor/sangue
5.
Toxicol Pathol ; 37(7): 902-10, 2009 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-19833913

RESUMO

The azole antifungal drug posaconazole caused phospholipidosis in neurons of the central nervous system, dorsal root ganglia of the spinal cord, and myenteric plexus in chronic toxicity studies in dogs. The time of onset, light and electron microscopic features, neurologic and electrophysiologic effects on the central and peripheral nervous systems, and potential for regression were investigated in a series of studies with a duration of up to one year. Nuclei of the medulla oblongata were the prominently affected areas of the brain. Neurons contained cytoplasmic vacuoles with concentrically whorled plasma membrane-like material (i.e., multilamellar bodies) morphologically identical to that commonly caused in other tissues by cationic amphiphilic drugs. Some axons in the brain and spinal cord were swollen and contained granular eosinophilic, electron-dense lysosomes. There were no features suggesting degeneration or necrosis of neurons or any associated elements of nervous tissue. The earliest and most consistent onset was in neurons of dorsal root ganglia. The observed neural phospholipidosis did not result in any alteration in the amplitude or latency of the auditory, visual, or somatosensory evoked potentials. The histopathologic changes did not progress or regress within the three-month postdose period. The results indicate that phospholipidosis can be induced in central and peripheral neurons of dogs by administration of posaconazole, but this change is not associated with functional effects in the systems evaluated.


Assuntos
Antifúngicos/toxicidade , Lipidoses/induzido quimicamente , Neurônios/efeitos dos fármacos , Fosfolipídeos/metabolismo , Triazóis/toxicidade , Animais , Antifúngicos/química , Cães , Gânglios Espinais/citologia , Gânglios Espinais/efeitos dos fármacos , Gânglios Espinais/metabolismo , Bulbo/efeitos dos fármacos , Bulbo/ultraestrutura , Plexo Mientérico/efeitos dos fármacos , Plexo Mientérico/metabolismo , Fibras Nervosas Mielinizadas/efeitos dos fármacos , Fibras Nervosas Mielinizadas/ultraestrutura , Neurônios/citologia , Neurônios/metabolismo , Tálamo/citologia , Tálamo/efeitos dos fármacos , Tálamo/metabolismo , Testes de Toxicidade Crônica , Triazóis/química
6.
Toxicol Pathol ; 30(6): 696-704, 2002.
Artigo em Inglês | MEDLINE | ID: mdl-12512871

RESUMO

The carcinogenic potential of chlorpromazine hydrochloride, a psychotropic agent, was assessed in the p53 heterozygous mouse assay. In a 4-week dose range finding study in p53 wild-type mice, doses of 20,40, 60, and 80 mg/kg were poorly tolerated because of mortality secondary to the severe sedative and hypotensive effects of chlorpromazine. Based on 40% mortality at a dose of 20 mg/kg in the dose-range finding study, a high dose of 10 mg/kg was chosen for the 26-week carcinogenicity study in p53 heterozygous mice. Doses of 2.5, 5, and 10 mg/kg chlorpromazine hydrochloride were well tolerated in the 26-week study. The administration of chlorpromazine hydrochloride at dose levels up to and including 10 mg/kg to p53 heterozygous and wild-type mice did not result in a dose-related increase in tumor incidence or in the type of tumors seen in comparison to controls. Findings related to the administration of chlorpromazine in the 26-week study were limited to minimal uterine and ovarian atrophy in p53 wild-type mice dosed with 10 mg/kg chlorpromazine hydrochloride. However, p53 heterozygous mice administered 400 mg/kg p-cresidine, a genotoxic carcinogen commonly used as a positive control for this model, developed urinary bladder tumors. Administration of p-cresidine also resulted in a regenerative anemia, splenic and hepatic hemosiderosis, renal findings, and ovarian and uterine atrophy. This study demonstrated that chlorpromazine hydrochloride, at the doses tolerated, was not carcinogenic in the p53 heterozygous mouse assay.


Assuntos
Compostos de Anilina/toxicidade , Antipsicóticos/toxicidade , Carcinógenos/toxicidade , Clorpromazina/toxicidade , Genes p53 , Neoplasias Experimentais/etiologia , Administração Oral , Compostos de Anilina/administração & dosagem , Animais , Antipsicóticos/administração & dosagem , Atrofia/induzido quimicamente , Atrofia/patologia , Peso Corporal/efeitos dos fármacos , Testes de Carcinogenicidade , Carcinoma/induzido quimicamente , Carcinoma/patologia , Clorpromazina/administração & dosagem , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Feminino , Genitália Feminina/efeitos dos fármacos , Genitália Feminina/patologia , Heterozigoto , Longevidade/efeitos dos fármacos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Tamanho do Órgão , Testes de Toxicidade Crônica , Neoplasias da Bexiga Urinária/induzido quimicamente , Neoplasias da Bexiga Urinária/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...